중증 근무력증의 최신지견
Recent Advances in Myasthenia Gravis
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Myasthenia gravis (MG) is one of the best-known autoimmune diseases, caused by autoantibodies directed to proteins in the postsynaptic muscle membrane of the neuromuscular junction (NMJ). It is characterized by fatigue and fluctuating weakness that worsens with activity. Involvement of respiratory muscles can cause a life-threatening crisis. A better understanding of immunopathogenic mechanism has led to the development of diagnosis and therapeutic interventions. This review summarizes advances in diagnostic and therapeutic aspects of MG: the change of epidemiologic characteristics; newly-discovered antigens; old and new investigational treatments.
Abstract
Myasthenia gravis (MG) is one of the best-known autoimmune diseases, caused by autoantibodies directed to proteins in the postsynaptic muscle membrane of the neuromuscular junction (NMJ). It is characterized by fatigue and fluctuating weakness that worsens with activity. Involvement of respiratory muscles can cause a life-threatening crisis. A better understanding of immunopathogenic mechanism has led to the development of diagnosis and therapeutic interventions. This review summarizes advances in diagnostic and therapeutic aspects of MG: the change of epidemiologic characteristics; newly-discovered antigens; old and new investigational treatments.
참고문헌 (21)
- Statland JM, "Myasthenia graivs five new things", Neurol Clin Pract, 3, pp.126~133 (2013)
- 김지영, "중증 근무력증에서 일어나는 신경근접합부의 면역병리학적 변화", 대한근전도 전기진단의학회지, 15(1), pp.6~10 (2013), 대한근전도전기진단의학회
- Evoli A, "Clinical characterstics and prognosis of myasthenia gravis in older people", J Am Geriatr Soc, 48, pp.1442~1448 (2000)
- Alkhawajah NM, "Late onset myasthenia gravis: A review when incidence in the older adults keeps increasing", Muscle Nerve, 24 (2013)
- Murai H, "Characteristics of myasthenia gravis according to onset-age: Japanese nationwide survey", J Neurol Sci, 305, pp.97~102 (2011)
- Aarli JA, "Myasthenia gravis in the elderly: Is it different?", Ann N Y Acad Sci, 1132, pp.238~243 (2008)
- Zivkovic´ SA, "Characteristics of late-onset myasthenia gravis", J Neurol, 259, pp.2167~2171 (2012)
- Donaldson DH, "The relationship of age to outcome in myasthenia gravis", Neurology, 40, pp.786~790 (1990)
- Suzuki S, "Clinical and immunological differences between early and late-onset myasthenia gravis in Japan", J Neuroimmunol, 230, pp.148~152 (2011)
- Zhang B, "Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis", Arch Neurol, 69, pp.445~451 (2012)
- Higuchi O, "Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis", Ann Neurol, 69, pp.418~422 (2011)
- Pevzner A, "Anti-LRP4 autoantibodies in AChRand MuSK-antibody-negative myasthenia gravis", J Neurol, 259, pp.427~435 (2012)
- Mori S, "Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic murine model of myasthenia gravis", Am J Pathol, 180, pp.798~810 (2012)
- Kawakami Y, "Anti-MuSK autoantibodies block binding of collagen Q to MuSK", Neurology, 77, pp.1819~1826 (2011)
- Barth D, "Comparison of IVIg and PLEX in patients with myasthenia gravis", Neurology, 76, pp.2017~2023 (2011)
- Dalakas MC, "Biologics and other novel approaches as new therapeutic options in myasthenia gravis: a view to the future", Ann N Y Acad Sci, 1274, pp.1~8 (2012)
- Howard JF Jr, "A randomized, double-blind, placebocontrolled phase II study of eculizumab in patients with refractory generalized myasthenia gravis", Muscle Nerve, 48, pp.76~84 (2013)
- Sussman J, "Further developments with antisense treatment for myasthenia gravis", Ann N Y Acad Sci, 1275, pp.13~16 (2012)
- Brenner T, "The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis", FASEB J, 17, pp.214~222 (2003)
- Pasnoor M, "Phase II trial of methotrexate in myasthenia gravis", Ann N Y Acad Sci, 1275, pp.23~28 (2012)
- Heckmann JM, "A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis", BMC Neurol, 11, pp.97~ (2011)